Finerenone(BAY94-8862)是第三代选择性、具有口服活性的、非甾体类盐皮质激素受体(MR)拮抗剂(IC50=18nM)。与糖皮质激素受体(GR)、雄激素受体(AR)和孕酮受体(AR)相比，Finerenone表现出良好的选择性(>500-fold)。Finerenone在心肾疾病研究中具有潜在的应用前景，如2型糖尿病和慢性肾脏疾病。
货号:ajcx30654
CAS:1050477-31-0
分子式:C21H22N4O3
分子量：378.42
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].

Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar FrÖmter (MWF) rat[1]. Animal Model: Twelve-week-old MWF rat[1]

[1]. BÄrfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [2]. GonzÁlez-BlÁzquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.